Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study
- 1 February 2010
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 69 (2) , 345-351
Abstract
Objectives: Anti-citrullinated peptide antibodies (ACPAs) are established as useful predictors of radiographic progression in rheumatoid arthritis (RA). The main objective of this study was to test the prognostic capacity of the recently developed test for anti-mutated citrullinated vimentin (anti-MCV). Methods: A cohort of 238 patients with RA was followed longitudinally for 10 years; 125 patients with complete x ray sets were included in the main analyses. Radiographs were scored according to the van der Heijde modified Sharp score (SHS). Patients were analysed for anti-MCV and anti-cyclic citrullinated peptide (CCP), and were genotyped for human leukocyte antigen (HLA)-DRB1 “shared epitope” (SE) and protein tyrosine phosphatase, non-receptor type 22 (PTPN22) 1858T. Results: Anti-MCV and anti-CCP were strongly associated with regard to status and level. Both antibodies were associated with SE, but only anti-MCV was significantly associated with PTPN22 1858T. A positive anti-MCV test increased the odds of radiographic progression by 7.3 (95% confidence interval (CI) 3.2 to 16.5) compared to 5.7 (95% CI 2.6 to 12.5) for a positive anti-CCP. Presence of MCV antibodies gave an average increase in the total SHS of 30 U compared to an average increase of 25 U for the presence of CCP antibodies. Anti-MCVs were more strongly associated to progression in erosions than joint space narrowing. Associations remained after adjustment for other predictors of radiographic progression. The odds of progression increased with increasing anti-MCV level. Conclusions: Presence of anti-MCV predicted joint damage, and the strength of this prediction was at least as strong as for anti-CCP. Antibody status showed a stronger association to bone than to cartilage destruction. This study also indicates that higher anti-MCV levels add prognostic information compared to their mere presence or absence.Keywords
This publication has 34 references indexed in Scilit:
- Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptidesArthritis & Rheumatism, 2007
- Fine specificity of the anti–citrullinated protein antibody response is influenced by the shared epitope allelesArthritis & Rheumatism, 2007
- Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritisArthritis & Rheumatism, 2007
- Long‐term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta‐analysisArthritis Care & Research, 2006
- The HLA–DRB1 shared epitope alleles are primarily a risk factor for anti–cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritisArthritis & Rheumatism, 2006
- Association of early radiographic damage with impaired physical function in rheumatoid arthritis: A ten‐year, longitudinal observational study in 238 patientsArthritis & Rheumatism, 2005
- Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA–DRB1 shared epitope for antibodies to citrullinated proteinsArthritis & Rheumatism, 2005
- The presence of citrullinated proteins is not specific for rheumatoid synovial tissueArthritis & Rheumatism, 2004
- The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptideArthritis & Rheumatism, 2000
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988